DSIP (Delta Sleep-Inducing Peptide)

Step	Weeks	Dose	Purpose
Days 1-3	—	100 mcg	Assess sleep response
Days 4-14	—	200-300 mcg	Full sleep optimization protocol

Beginner Protocol

Intermediate Protocol

Advanced Protocol

Reconstitution and handling notes

Stacking Notes

Additional Dosage Notes

The Evidence Landscape: Thin and Dated

DSIP's clinical evidence base is genuinely thin and poorly suited to modern regulatory or evidence-based medicine standards. Almost all human studies were conducted between the late 1970s and early 1990s, primarily in Western and Eastern Europe, with small sample sizes (6-107 subjects), inconsistent outcome measures, near-universal use of intravenous dosing (not the subcutaneous or intranasal routes sold today), and methodology that would not pass modern peer review. There has never been a large (N>200), well-powered, placebo-controlled, independently-replicated trial of DSIP for any indication, and the sleep results across groups are openly contradictory. This is critical context for interpreting the literature.

With that framing established, the following studies represent the actual published human evidence:

Insomnia and Sleep Disorders (Mixed, Ultimately Unconvincing)

Schneider-Helmert & Schoenenberger, 1981 (PMID [7028502]): Synthetic DSIP 25 nmol/kg IV in 6 middle-aged chronic insomniacs produced longer sleep duration and higher subjective quality with no daytime sedation; the sleep-promoting effect appeared mainly in the second hour after injection.

Schneider-Helmert et al., 1981 (PMID [6895513]): In 6 healthy volunteers, morning IV DSIP (25 nmol/kg) increased sleep by roughly 59% over a 130-minute window without classic pharmacologic sedation, and was well tolerated.

Schneider-Helmert, Graf & Schoenenberger, 1981 (PMID [6112579]): Early Lancet report describing improved sleep in insomniacs with synthetic DSIP.

Schneider-Helmert, 1987 (PMID [3622582]): Placebo-controlled, double-blind trial in 14 middle-aged chronic insomniacs dosed for 7 consecutive nights. Reported substantially improved night sleep plus improved daytime alertness and performance - one of the more positive controlled results.

Monti et al., 1987 (PMID [3583493]): Double-blind crossover of DSIP 25 nmol/kg IV in chronic insomniacs. Although a few sleep parameters shifted, the authors concluded that sleep improvement under DSIP treatment is "of little clinical significance" - a directly negative read.

Bes et al., 1992 (PMID [1299794]): Double-blind randomized trial in 16 chronic insomniacs. Found only weak, statistically fragile effects and concluded that short-term DSIP treatment "is not likely to be of major therapeutic benefit."

Honestly summarized: the early open and small controlled studies from the originating group were positive, while independent replications were weak or negative. That is the classic signature of a modest, highly variable effect that never consolidated into reproducible efficacy - which is also why the compound's marketing name overstates what the trials actually show.

Alcohol and Opioid Withdrawal

Dick, Grandjean & Tissot, 1983 (PMID [6328354]): IV DSIP (25 nmol/kg) as sole treatment in 67 patients in alcohol or opiate withdrawal; of 49 evaluable patients, 48 showed rapid relief of somatic withdrawal signs, with anxiety resolving more slowly and no major side effects.

Dick et al., 1984 (PMID [6548969]): Larger open series of 107 inpatients in alcohol (n=47) or opiate (n=60) withdrawal treated with IV DSIP; the great majority improved rapidly, with opiate withdrawal requiring more injections than alcohol.

These withdrawal results are the most striking in the DSIP literature, but they come from a single group using uncontrolled, open-label designs, so they remain hypothesis-generating rather than confirmed.

Chronic Pain

Larbig et al., 1984 (PMID [6548970]): Open clinical pilot in 7 patients with chronic pain (migraine/vasomotor headache, chronic tinnitus, psychogenic pain). IV DSIP lowered pain in 6 of 7 and reduced concomitant depressive symptoms. Very small and uncontrolled.

Stress and HPA-Axis Effects (Preclinical)

Graf, Kastin, Coy & Fischman, 1985 (PMID [2995861]): In rats, IV DSIP (5-30 ug/kg) significantly reduced CRF-stimulated corticosterone release but did not affect ACTH-stimulated release, suggesting DSIP dampens the stress axis at the pituitary level. This is the clearest mechanistic support for DSIP's reputed anti-stress effect - but it is animal data, not a human clinical outcome.

Reviews and Endogenous DSIP

Graf & Kastin, 1986 (PMID [3550726]): Authoritative review of DSIP isolation, sleep and extra-sleep effects, and therapeutic exploration in insomnia, pain, and withdrawal; concluded that the primary mechanism (possibly adrenergic modulation) remained unestablished.

Constantinidis et al., 1983 (PMID [6371576]) and Ernst et al., 1987 (PMID [2448424]): Endogenous DSIP-like immunoreactivity has been mapped in rat brain and measured in human cerebrospinal fluid, where levels rise with age and fall in several dementias - consistent with an endogenous regulatory peptide present at very low (picomolar) concentrations.

A frequently repeated claim that DSIP has "antidepressant" activity traces to uncontrolled case series only and has never been confirmed in a controlled trial; it should not be treated as established.

What the Evidence Actually Supports

Honestly interpreted, the DSIP literature supports:

• Subjective sleep improvement in a subset of responders - not a universal or dramatic effect
• Mild stress-modulating activity - more consistent than sleep effects, though largely preclinical
• Possible adjunctive role in withdrawal syndromes - striking open-label reports, but unconfirmed
• Excellent tolerability and safety at typical doses - no serious adverse events reported in any controlled trial
• Non-addictive, non-dependence-producing profile - a legitimate advantage over benzodiazepines

What the Evidence Does NOT Support

• Strong, reliable sleep induction comparable to z-drugs or benzodiazepines
• Clinical use for chronic pain at the evidence level of established analgesics
• Antidepressant efficacy
• Any claim of "repair," "restoration," or "regeneration"
• Use in pediatric populations
• Use as a primary therapy for severe insomnia or sleep apnea

Why the Evidence Remains Thin

Several factors have kept DSIP research in a backwater:

1. No patent protection - DSIP is a natural peptide; no company could profit from developing it, removing incentive for large trials.
2. Pharmacological complexity - the absent receptor and inconsistent effects made drug development uncertain.
3. Regulatory disinterest - small-molecule sleep agents dominated the field and captured regulatory and commercial attention.
4. Russian/Eastern European clinical literature - substantial DSIP clinical work was done in these settings but often not published in English-language journals or not meeting Western methodological standards.
5. Research chemical market capture - DSIP entered the gray-market peptide space and now exists commercially without clinical trial infrastructure to generate new evidence.

Real-World Use Patterns

Despite the thin evidence, DSIP is widely used in the biohacking and functional medicine community, with typical self-reported patterns:

• Evening subcutaneous injection (100-300 mcg) 30-60 minutes before bed
• Intermittent use rather than nightly (to avoid any theoretical tolerance)
• Often stacked with other sleep-promoting agents (melatonin, magnesium, glycine, GABA, apigenin)
• Subjective reports bimodally distributed - strong responders and non-responders, fewer "somewhat helps" reports
• Very low rate of reported side effects
• No addiction, withdrawal, or tolerance syndromes reported after discontinuation

This real-world pattern is consistent with a compound that has genuine but modest pharmacological activity with high inter-individual response variability - which matches the trial data and the inferred pharmacology.

Overall Safety Profile

DSIP has one of the cleanest safety profiles of any peptide in the research chemical space. In 40+ years of research and clinical use, no serious adverse events have been reported in controlled trials or large case series. The compound lacks the significant liabilities of benzodiazepines (dependence, withdrawal, cognitive impairment), z-drugs (complex sleep behaviors, hangover, tolerance), or sedating antihistamines (anticholinergic effects, next-day grogginess). This favorable safety profile is one of the main reasons DSIP has retained a user base despite modest efficacy.

That said, "no serious adverse events in controlled trials" reflects a relatively small aggregate patient exposure — probably a few hundred patients in all published trials combined. Rare but important adverse events would not necessarily have been detected at that exposure level. The following side effects have been reported in trials and post-marketing use:

Common Side Effects (5-15% of users)

• Drowsiness or grogginess next morning: Especially with higher doses or late-night injection. Usually resolves within a few hours of waking. More common in slow metabolizers or those dosing above 300 mcg.
• Vivid dreams: Some users report unusually vivid or memorable dreams, sometimes including lucid dreaming. Generally neutral or positive but can be disruptive in some users.
• Injection site reactions (for SC users): Mild redness, slight swelling, or transient discomfort at the injection site. Resolves within hours. Proper injection technique and site rotation minimize.
• Nasal irritation (for intranasal users): Mild burning, dryness, or congestion from the spray vehicle rather than DSIP itself. Usually short-lived.

Uncommon Side Effects (1-5%)

• Headache: Mild, usually self-limiting. More common in first 1-2 uses.
• Dizziness: Usually mild; rare.
• Nausea: Uncommon; mostly anecdotal.
• Mood changes: A minority of users report subtle mood effects, either positive (calm, contentment) or neutral (emotional blunting). True dysphoric reactions are rare.
• Mild fatigue into next day: Usually resolves with dose reduction.

Rare Side Effects (<1% or case reports)

• Sleep disruption (paradoxical): A small subset of users report WORSE sleep with DSIP — restless nights, early awakening, or vivid dreams preventing sleep. Not a common reaction but worth noting.
• Feeling of disinhibition: Rare reports of mild euphoric or disinhibited feeling, usually at higher doses; not addictive but occasionally pleasant.
• Allergic reactions: Theoretical risk of injection site reaction or systemic allergic response. Rare but possible with any peptide.

What Has NOT Been Reported

Reassuringly, DSIP has NOT been associated with:

• Dependence or withdrawal syndrome
• Tolerance to sleep effects (though some report diminished response with very frequent use)
• Cognitive impairment or memory effects
• Respiratory depression (major advantage over benzodiazepines, opioids)
• Cardiovascular effects
• Driving impairment
• Morning rebound insomnia
• Complex sleep behaviors (sleep-eating, sleep-driving — issues with z-drugs)
• Paradoxical aggression or behavioral disturbance
• Drug interactions of major clinical consequence (though formal interaction studies are limited)
• Effects on hormones outside of acute transient changes

Dose-Dependent Patterns

Side effects are generally mild and dose-dependent:

• 100 mcg SC: minimal to no side effects in most users
• 200 mcg SC: occasional mild next-day grogginess; vivid dreams more common
• 300 mcg SC: higher chance of morning grogginess, more vivid dreams
• 500+ mcg SC: often produces lingering effects into next day; not typically recommended

Intranasal vs. Subcutaneous Tolerability

Intranasal DSIP generally produces milder side effects than subcutaneous, likely due to:

• Lower systemic peptide exposure (less absorbed intranasally)
• Absence of injection-site reactions
• Possibly different CNS distribution pattern

However, intranasal also appears to produce somewhat less sleep benefit in responders compared to SC, reflecting the dose/exposure trade-off.

Long-Term Use Considerations

Long-term safety data is essentially absent. The oldest controlled trials treated subjects for a few weeks. Post-marketing surveillance from research chemical suppliers does not exist in a systematic form. Users who have used DSIP chronically for years generally report no obvious issues, but this is anecdotal. Prudent practice:

• Intermittent rather than continuous use
• Dose cycles (e.g., 5 nights on, 2 nights off; or every other night)
• Periodic breaks (e.g., 2-4 weeks off every 3-6 months)
• Focus on underlying sleep hygiene rather than indefinite pharmacological dependence on a sleep aid (even a benign one)

Special Populations

• Pregnancy/lactation: No data. Avoid.
• Elderly: Probably tolerated but may be more prone to next-day effects; start lower doses.
• Hepatic/renal impairment: Limited data; peptide clearance pathways may be altered.
• Cognitive impairment: Generally considered safe but monitor carefully; not a first-line sleep aid in dementia.
• Children/adolescents: No data. Should not be used.
• History of substance use disorder: DSIP has no known addiction liability, but behavioral patterns around any sleep aid merit attention.

Adverse Reaction Management

If side effects occur:

• Minor drowsiness/grogginess: Reduce dose by 50%, dose earlier in evening
• Vivid dreams to the point of disruption: Consider dose reduction or drug holiday
• Injection site reaction: Rotate sites, use smaller needle (31g insulin syringe), improved technique
• Nasal irritation: Check product quality, consider alternate delivery route
• Any concerning or unexpected reaction: Discontinue, evaluate with physician
• Suspected allergic reaction: Discontinue immediately, seek medical attention

Mar 13